THYROCARE TECHNOLOGIES Share Price Today Down 6%: What’s Behind the Drop?
Market Insights
The Indian stock market is experiencing a volatile day, with the THYROCARE TECHNOLOGIES share price taking a significant hit. As of now, the company’s stock is trading at Rs 678.0, down 6% from its previous closing price. But what’s behind this sudden plunge? In this article, we’ll delve into the factors contributing to the decline.
Market Insights: BSE HEALTHCARE Index
The BSE HEALTHCARE index, which THYROCARE TECHNOLOGIES is a part of, is also experiencing a tumultuous day. The index is currently down 2.0%, with several top losers in the sector.
Losers in BSE HEALTHCARE Index
- GRANULES INDIA is down 7.6%
- SUN PHARMA ADV. RES. is down 6.3%
Gain in BSE HEALTHCARE Index
On the other hand, J.B.Chemicals is one of the top gainers today, with a 0.5% increase.
Long-Term Performance of THYROCARE TECHNOLOGIES
Over the last one year, THYROCARE TECHNOLOGIES has moved up from Rs 629.6 to Rs 678.0, registering a gain of Rs 48.5 (up 7.7%). This impressive growth can be attributed to the company’s consistent performance and strategic decisions.
Long-Term Performance of BSE HEALTHCARE Index
The BSE HEALTHCARE index has also shown significant growth over the last 12 months, moving up from 35,495.1 to 38,295.1, registering a gain of 7.9%.
Top Gainers in BSE HEALTHCARE Index
- SUVEN PHARMACEUTICALS (up 71.6%)
- Jubilant Pharmova (up 55.2%)
- Divis Laboratories (up 50.8%)
What About the Benchmark Indices?
The BSE Sensex is currently at 73,638.3, down 1.3%. Top losers in the BSE Sensex include:
- Indusind Bank (down 5.5%)
- Tech Mahindra (down 5.3%)
Financial Update: THYROCARE TECHNOLOGIES
THYROCARE TECHNOLOGIES has reported a notable increase in its financial performance. For the quarter ended December 2024, the company’s net profit grew 30.8% YoY to Rs 191 million, compared to a profit of Rs 146 million a year ago. Net sales rose 23.1% to Rs 1,659 million during the period.
Long-Term Financial Performance of THYROCARE TECHNOLOGIES
For the year ended March 2024, THYROCARE TECHNOLOGIES reported an 8.0% increase in net profit to Rs 695 million compared to net profit of Rs 644 million during FY23. Revenue of the company grew 8.6% to Rs 5,719 million during FY24.
Current Valuation of THYROCARE TECHNOLOGIES
Considering the current market volatility, it’s essential to evaluate the company’s valuation. The current Price to earnings ratio of THYROCARE TECHNOLOGIES, based on rolling 12-month earnings, stands at 41.1.
As we navigate the dynamic market, it’s crucial to stay informed and make informed decisions. Will THYROCARE TECHNOLOGIES recover from this recent decline, or will it continue on its downward trend? Only time will tell. For now, let’s continue to monitor the company’s performance and adjust our expectations accordingly.
Live News Daily is a trusted name in the digital news space, delivering accurate, timely, and in-depth reporting on a wide range of topics.